​
​

AN2 Therapeutics (ANTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ANTX Stock Forecast

AN2 Therapeutics stock forecast is as follows: an average price target of $8.75 (represents a 573.08% upside from ANTX’s last price of $1.30) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ANTX Price Target

The average price target for AN2 Therapeutics (ANTX) is $8.75 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $22.00 to $2.00. This represents a potential 573.08% upside from ANTX's last price of $1.30.

ANTX Analyst Ratings

Buy

According to 3 Wall Street analysts, AN2 Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ANTX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

AN2 Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 03, 2024Joseph SchwartzLeerink Partners$5.00$2.13134.74%284.62%
May 16, 2024Liisa BaykoEvercore ISI$2.00$2.27-11.89%53.85%
Apr 02, 2024Roy BuchananJMP Securities$6.00$3.7659.57%361.54%
Nov 14, 2022-Leerink Partners$25.00$14.8768.12%1823.08%
Apr 19, 2022-Evercore ISI$25.00$14.0078.57%1823.08%
Apr 19, 2022-Oppenheimer$22.00$14.7249.46%1592.31%
Row per page
Go to

The latest AN2 Therapeutics stock forecast, released on Jul 03, 2024 by Joseph Schwartz from Leerink Partners, set a price target of $5.00, which represents a 134.74% increase from the stock price at the time of the forecast ($2.13), and a 284.62% increase from ANTX last price ($1.30).

AN2 Therapeutics Price Target by Period

1M3M12M
# Anlaysts--3
Avg Price Target--$4.33
Last Closing Price$1.30$1.30$1.30
Upside/Downside-100.00%-100.00%233.08%

In the current month, the average price target of AN2 Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AN2 Therapeutics's last price of $1.30. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Aug 09, 2024Evercore ISI-UnderperformDowngrade
Jul 03, 2024Leerink PartnersMarket PerformOutperformUpgrade
Apr 02, 2024JMP Securities-OutperformUpgrade
Feb 13, 2024Leerink Partners-Market PerformDowngrade
Nov 14, 2022SVB LeerinkOutperformOutperformHold
Row per page
Go to

AN2 Therapeutics's last stock rating was published by Evercore ISI on Aug 09, 2024. The company Downgrade its ANTX rating from "null" to "Underperform".

AN2 Therapeutics Financial Forecast

AN2 Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
# Analysts-----------
Surprise %-----------

AN2 Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ANTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

AN2 Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict ANTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than AN2 Therapeutics's previous annual EBITDA (undefined) of $NaN.

AN2 Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
Net Income-----------
Avg Forecast$-8.36M$-8.36M$-8.06M$-7.76M$-7.66M$-7.96M$-7.06M$-7.36M$-8.00M$-13.43M$-18.07M
High Forecast$-8.36M$-8.36M$-8.06M$-7.76M$-7.66M$-7.96M$-7.06M$-7.36M$-7.27M$-13.43M$-18.07M
Low Forecast$-8.36M$-8.36M$-8.06M$-7.76M$-7.66M$-7.96M$-7.06M$-7.36M$-8.72M$-13.43M$-18.07M
Surprise %-----------

AN2 Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ANTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

AN2 Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

AN2 Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ANTX last annual SG&A of $NaN (undefined).

AN2 Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EPS-----------
Avg Forecast$-0.28$-0.28$-0.27$-0.26$-0.26$-0.27$-0.24$-0.25$-0.27$-0.45$-0.61
High Forecast$-0.28$-0.28$-0.27$-0.26$-0.26$-0.27$-0.24$-0.25$-0.24$-0.45$-0.61
Low Forecast$-0.28$-0.28$-0.27$-0.26$-0.26$-0.27$-0.24$-0.25$-0.29$-0.45$-0.61
Surprise %-----------

According to undefined Wall Street analysts, AN2 Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ANTX previous annual EPS of $NaN (undefined).

AN2 Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PMVPPMV Pharmaceuticals$1.57$18.001046.50%Buy
ANTXAN2 Therapeutics$1.30$8.75573.08%Buy
PEPGPepGen$4.40$29.50570.45%Buy
MOLNMolecular Partners$5.20$29.00457.69%Buy
AVTEAerovate Therapeutics$2.66$13.00388.72%Hold
ANEBAnebulo Pharmaceuticals$1.52$6.00294.74%Buy
ACRVAcrivon Therapeutics$6.50$21.83235.85%Buy
RZLTRezolute$5.01$13.50169.46%Buy
ELYMEliem Therapeutics$5.11$13.00154.40%Buy
ADAGAdagene$2.09$5.00139.23%Buy
MLYSMineralys Therapeutics$12.60$30.00138.10%Buy
PHVSPharvaris$20.50$39.6793.51%Buy

ANTX Forecast FAQ

Is AN2 Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, AN2 Therapeutics (ANTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ANTX's total ratings.

What is ANTX's price target?

AN2 Therapeutics (ANTX) average price target is $8.75 with a range of $2 to $22, implying a 573.08% from its last price of $1.3. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will AN2 Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ANTX stock, the company can go up by 573.08% (from the last price of $1.3 to the average price target of $8.75), up by 1592.31% based on the highest stock price target, and up by 53.85% based on the lowest stock price target.

Can AN2 Therapeutics stock reach $2?

ANTX's average twelve months analyst stock price target of $8.75 supports the claim that AN2 Therapeutics can reach $2 in the near future.

What are AN2 Therapeutics's analysts' financial forecasts?

AN2 Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-30.041M (high $-30.041M, low $-30.041M), average SG&A $0 (high $0, low $0), and average EPS is $-1.007 (high $-1.007, low $-1.007). ANTX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-32.527M (high $-32.527M, low $-32.527M), average SG&A $0 (high $0, low $0), and average EPS is $-1.09 (high $-1.09, low $-1.09).